Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
922studies shown
Showing 26-50 of 922
RecruitingNCT06963021

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study is recruiting. It focuses on depression and currently lists participation information in Belgium, Canada, Finland, Hungary, Latvia, the United Kingdom, and the United States.

DepressionOtherOver 18 Years
Countries
Belgium, Canada, Finland, Hungary, Latvia, United Kingdom, United States
Sponsor
Neurocrine Biosciences
Condition
Depression
RecruitingNCT06557642

Nitrous Oxide and EMOtional Cognition

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom.

DepressionDrugFrom 18 Years to 40 Years
Countries
United Kingdom
Sponsor
University of Oxford
Condition
Depression
RecruitingNCT05973851

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study is recruiting. It focuses on depression and currently lists participation information in Austria, Germany, Greece, Italy, Spain, and the United Kingdom.

DepressionDrugFrom 18 Years to 65 Years
Countries
Austria, Germany, Greece, Italy, Spain, United Kingdom
Sponsor
Dr. Inge Winter
Condition
Depression
RecruitingNCT03645447

The Taste-Mood Diagnostic Study

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom.

DepressionDiagnostic TestOver 18 Years
Countries
United Kingdom
Sponsor
Ranvier Health Ltd
Condition
Depression
RecruitingNCT06309472

Trial of Mirtazapine for Depression in IBD

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom.

DepressionDrugFrom 18 Years to 125 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Depression
RecruitingNCT06604104

Visual Frailty in Ageing

This study is recruiting. It focuses on anxiety and currently lists participation information in the United Kingdom.

AnxietyOtherOver 60 Years
Countries
United Kingdom
Sponsor
University of Edinburgh
Condition
Anxiety
RecruitingNCT05862636

Who Fares Best With Mindfulness Meditation

This study is recruiting. It focuses on depression and currently lists participation information in Belgium and the United Kingdom.

DepressionBehavioralOver 18 Years
Countries
Belgium, United Kingdom
Sponsor
Prof. dr. Filip Raes
Condition
Depression
RecruitingNCT06687694

Immune Mechanisms of Antipsychotic Treatment Response

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
RecruitingNCT05304767

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Bulgaria, Czech Republic, India, Japan, Poland, Romania, Serbia, the United Kingdom, and the United States.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Bulgaria, Czech Republic, India, Japan, Poland, Romania, Serbia, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07419321

Social Isolation and Aging in Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the Netherlands, Spain, the United Kingdom, and the United States.

SchizophreniaOtherFrom 40 Years to 70 Years
Countries
Netherlands, Spain, United Kingdom, United States
Sponsor
Icahn School of Medicine at Mount Sinai
Condition
Schizophrenia
RecruitingNCT05656469

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

This study is recruiting. It focuses on anxiety and currently lists participation information in Germany, the Netherlands, Romania, Serbia, Spain, the United Kingdom, and the United States.

AnxietyOtherFrom 16 Years to 65 Years
Countries
Germany, Netherlands, Romania, Serbia, Spain, United Kingdom, United States
Sponsor
Maastricht University Medical Center
Condition
Anxiety
RecruitingNCT07196423

Early Psychosis: Investigating Cognition

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United Kingdom
Sponsor
University of Nottingham
Condition
Schizophrenia
RecruitingNCT05958875

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Germany, Italy, Spain, and the United Kingdom.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Austria, Germany, Italy, Spain, United Kingdom
Sponsor
Dr. Inge Winter
Condition
Schizophrenia
RecruitingNCT06236048

Energetics and Glutamate in Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
RecruitingNCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, the United Kingdom, and the United States.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia